001) than those in the normal adjacent mucosa (Figure 1). Figure 1 Quantitative reverse transcription-PCR showed mRNA MS-275 nmr expression of ANKRD12 in CRC tumor tissues (T) and adjacent normal mucosa (N). ANKRD12 expression levels were lower in tumor tissue than in normal adjacent mucosa (p < 0.001, Student’s t test). Relationship between ANKRD12 mRNA expression and clinicopathological features The mRNA expression of the ANKRD12 was categorized as low or high in relation to the median value.
The experimental samples were divided into two groups [the selleck chemicals high ANKRD12 expression group (n = 34) and the low ANKRD12 expression group (n = 34)] to investigate ANKRD12 mRNA expression in association with clinicopathologic variables (Table 1). The ANKRD12 mRNA expression was not related to age, gender, histological see more type, depth of invasion(T), lymph node metastasis, tumor location. However, the incidence in liver metastasis was significantly higher (P = 0.015) in the low expression group (14 of 34, 41.2%) than in the high expression group (5
of 34, 14.7%), and the incidence of cancer death was significantly higher (P = 0.015) in the low expression group (22 of 34, 64.7%) than in the high expression group (12 of 34, 35.3%). Table 1 Clinicopathologic variables and ANKRD12 mRNA expression in 68 colorectal cancers Variables Expression P value ANKRD12 high ANKRD12 low (n = 34) (n = 34) Age 58.0 ± 15.0 61.6 ± 14.1 0.309 Sex 0.215 Male 18 23 Female 16 11 Histological type 0.793 Well, Moderate 23 24 Poor and others 11 10 Depth of invasion 0.380 T1,2,3 25 28 T4 9 GNA12 6 Location 0.086 Colon 23 16 Rectum 11 18 Lymph node metastasis 0.209 Absent 15 10 Present 19 24 Liver metastasis 0.015* Absent 29 20 Present 5 14 Cancer-related death 0.015* Alive 22 12 Death 12 22 n Number of patients, * <0.05. ANKRD12 mRNA expression and prognosis of CRC patients Overall survival
curves were plotted according to ANKRD12 mRNA expression by the Kaplan–Meier method. In the study group of CRC without liver metastasis (49 patients), the overall survival rate was significantly lower in the patients with low ANKRD12 mRNA expression than that in those with high expression (P = 0.041; Figure 2). Figure 2 Kaplan-Meier survival curves of CRC patients without liver metastasis according to the status of ANKRD12 expression. Patients with low ANKRD12 mRNA expression showed significantly poorer prognosis than those with high ANKRD12 mRNA expression (P = 0.041, log-rank test). Univariate analysis with Cox proportional hazards model identified four prognostic factors: location, lymph node metastasis, liver metastasis, and ANKRD12 expression. The other clinicopathological features, such as age, gender, histological type and depth of invasion were not statistically significant prognosis factors (Table 2).